Department of Medicine, Center for Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Hepatology. 2014 Nov;60(5):1483-93. doi: 10.1002/hep.27159. Epub 2014 May 19.
Chronic hepatitis B virus (HBV) infection has been associated with alterations in lipid metabolism. Moreover, the Na+-taurocholate cotransporting polypeptide (NTCP), responsible for bile acid (BA) uptake into hepatocytes, was identified as the functional cellular receptor mediating HBV entry. The aim of the study was to determine whether HBV alters the liver metabolic profile by employing HBV-infected and uninfected human liver chimeric mice. Humanized urokinase plasminogen activator/severe combined immunodeficiency mice were used to establish chronic HBV infection. Gene expression profiles were determined by real-time polymerase chain reaction using primers specifically recognizing transcripts of either human or murine origin. Liver biopsy samples obtained from HBV-chronic individuals were used to validate changes determined in mice. Besides modest changes in lipid metabolism, HBV-infected mice displayed a significant enhancement of human cholesterol 7α-hydroxylase (human [h]CYP7A1; median 12-fold induction; P<0.0001), the rate-limiting enzyme promoting the conversion of cholesterol to BAs, and of genes involved in transcriptional regulation, biosynthesis, and uptake of cholesterol (human sterol-regulatory element-binding protein 2, human 3-hydroxy-3-methylglutaryl-coenzyme A reductase, and human low-density lipoprotein receptor), compared to uninfected controls. Significant hCYP7A1 induction and reduction of human small heterodimer partner, the corepressor of hCYP7A1 transcription, was also confirmed in liver biopsies from HBV-infected patients. Notably, administration of Myrcludex-B, an entry inhibitor derived from the pre-S1 domain of the HBV envelope, provoked a comparable murine CYP7A1 induction in uninfected mice, thus designating the pre-S1 domain as the viral component triggering such metabolic alterations.
Binding of HBV to NTCP limits its function, thus promoting compensatory BA synthesis and cholesterol provision. The intimate link determined between HBV and liver metabolism underlines the importance to exploit further metabolic pathways, as well as possible NTCP-related viral-drug interactions.
慢性乙型肝炎病毒(HBV)感染与脂质代谢改变有关。此外,负责胆汁酸(BA)摄取到肝细胞的钠离子-牛磺胆酸共转运多肽(NTCP)被鉴定为介导 HBV 进入的功能性细胞受体。本研究的目的是通过使用 HBV 感染和未感染的人肝嵌合小鼠来确定 HBV 是否通过改变肝脏代谢谱。使用人尿激酶型纤溶酶原激活物/严重联合免疫缺陷小鼠建立慢性 HBV 感染。通过实时聚合酶链反应,使用特异性识别人或鼠来源转录本的引物确定基因表达谱。从 HBV 慢性个体获得的肝活检样本用于验证在小鼠中确定的变化。除了脂质代谢的适度变化外,HBV 感染的小鼠还显示出人类胆固醇 7α-羟化酶(人类 [h]CYP7A1;中位数 12 倍诱导;P<0.0001)的显著增强,该酶促进胆固醇转化为 BA,以及参与转录调节、生物合成和胆固醇摄取的基因(人类固醇调节元件结合蛋白 2、人类 3-羟-3-甲基戊二酰辅酶 A 还原酶和人类低密度脂蛋白受体),与未感染的对照相比。在 HBV 感染患者的肝活检中也证实了 hCYP7A1 诱导的显著增加和 hCYP7A1 转录的核心抑制因子人类小异二聚体伴侣的减少。值得注意的是,施用 Myrcludex-B,一种源自 HBV 包膜前 S1 结构域的进入抑制剂,在未感染的小鼠中引起类似的小鼠 CYP7A1 诱导,从而将前 S1 结构域指定为触发这种代谢改变的病毒成分。
HBV 与 NTCP 的结合限制了其功能,从而促进了代偿性 BA 合成和胆固醇供应。HBV 与肝脏代谢之间确定的密切联系强调了进一步利用代谢途径以及可能的 NTCP 相关病毒-药物相互作用的重要性。